RO 7300490
Alternative Names: Bispecific FAP-CD40 antibody; Bispecific FAP-huCD40 antibody; FAP-CD40; FAP-huCD40; Fibroblast activation Protein-α (FAP) targeted CD40 agonist; RG-6189; RO-7300490Latest Information Update: 26 Feb 2024
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Feb 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark (IV) (Roche pipeline, February 2024)
- 15 Feb 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) (Roche pipeline, February 2024)
- 15 Feb 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV) (Roche pipeline, February 2024)